Acadian Asset Management’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Acadian Asset Management’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-263	Closed	-$26K	–	1931
2024 Q1	$26K	Sell	263 -1,829	-87%	-$116K	﹤0.01%	1459
2023 Q4	$48K	Hold	2,092	–	–	﹤0.01%	1467
2023 Q3	$42K	Hold	2,092	–	–	﹤0.01%	1452
2023 Q2	$53K	Hold	2,092	–	–	﹤0.01%	1523
2023 Q1	$42K	Hold	2,092	–	–	﹤0.01%	1543
2022 Q4	$41K	Hold	2,092	–	–	﹤0.01%	1607
2022 Q3	$56K	Buy	2,092 +857	+69%	+$24.7K	﹤0.01%	1482
2022 Q2	$33K	Buy	+1,235	New	+$54.9K	﹤0.01%	1560

Other funds holding VINC

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management's VINC Position: Q2 2024 in Review

Acadian Asset Management sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2024, closing a stake of 263 shares — an estimated $26K sold.

Acadian Asset Management first reported a position in VINC in Q2 2022 and held it in 8 quarters. The position peaked at $56K in Q3 2022. 27 funds tracked by Wall St. Rank hold VINC as of Q2 2024.

Acadian Asset Management reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Acadian Asset Management sold 263 Vincerx Pharma, Inc. Common Stock shares in Q2 2024, an estimated $26K.
Acadian Asset Management first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2022 and held it in 8 quarters.
Acadian Asset Management's Vincerx Pharma, Inc. Common Stock position peaked at $56K in Q3 2022.
27 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2024.

Based on Acadian Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.